Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

2361. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients

Inhibitors /economics /therapeutic use; Captopril /economics /therapeutic use; Cohort Studies; Diabetes Mellitus, Type 1 /complications /economics; Diabetic Nephropathies /drug therapy; Disease Progression; England; Health Care Costs /statistics & Humans; Kidney Failure, Chronic /economics /etiology /prevention & Middle Aged; Models, Econometric; Sensitivity and Specificity; control; numerical data AccessionNumber 21997000623 Date bibliographic record published 31/03/1999 Date abstract record published (...) Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Hendry B M, Viberti G C, Hummel S, Bagust A, Piercy J Record Status This is a critical abstract

1997 NHS Economic Evaluation Database.

2362. Metformin: an antihyperglycemic agent for treatment of type II diabetes

Metformin: an antihyperglycemic agent for treatment of type II diabetes Metformin: an antihyperglycemic agent for treatment of type II diabetes Metformin: an antihyperglycemic agent for treatment of type II diabetes Melchior W R, Jaber L A Authors' objectives To review the comparative efficacy of metformin, sulfonylureas, and insulin in the treatment of patients with type II diabetes. Searching MEDLINE was searched from 1966 to 1994 for articles published in English, French or German, using (...) compared, although study design, treatment regime and dosage, and outcome measures varied. Metformin is as effective as the sulfonylureas in treating patients with type II diabetes and has a more prominent postprandial effect than sulfonylureas or insulin. When combined with sulfonylurea, metformin exerts antihyperglycaemic effects above those provided by the sulfonylurea with which it is combined. Adverse effects include reduced absorption of vitamin B12 and folic acid, as well as gastrointestinal

1996 DARE.

2363. Promoting weight loss in type II diabetes

M, Upchurch S, Ramirez G, Anding R. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19(6): 613-624 PubMedID Other publications of related interest 1. Glass GV, McGraw B, Smith ML. Meta-analysis in social research. Beverly Hills (CA): Sage Publications; 1981. 2. Hedges LV, Olkin I. Statistical methods for meta-analysis. New York: Academic Press; 1985. 3. Richter B. Meta-analysis: dietary strategies alone reduce weight best in NIDDM. ACP J Club 1997;126:5. Indexing Status Subject (...) Promoting weight loss in type II diabetes Promoting weight loss in type II diabetes Promoting weight loss in type II diabetes Brown S A, Winter M, Upchurch S, Ramirez G, Anding R Authors' objectives To examine the effectiveness of behavioural therapies, exercise, diet, anorectic drugs, surgery or a combination of strategies in promoting weight loss in people with type II diabetes. Searching MEDLINE was searched from 1966 to 1994, Combined Health Information Database from 1978 to 1994

1996 DARE.

2364. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials

-conducted meta-analysis with clear inclusion and exclusion criteria. However, limiting the included studies to English language papers may introduce an element of bias. Bibliographic details Johnson J L, Wolf S L, Kubadi U M. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials. Archives of Internal Medicine 1996; 156(3): 259-264 PubMedID Other publications of related interest 1. Moody L. Meta-analysis: qualitative (...) Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials Johnson J L, Wolf S L, Kubadi U M Authors' objectives To assess the efficacy

1996 DARE.

2365. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus

Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus Steindel B S, Roe T R, Costin G, Carlson M, Kaufman F R Record Status This is a critical abstract (...) breakdown of costs and without quantities and prices it is impossible to generalise from this study. No attempt was made to cost outpatient visits or telephone contacts. These formed a high proportion of the care of diabetes patients and it was not demonstrated that the same costs apply under both regimes. Bibliographic details Steindel B S, Roe T R, Costin G, Carlson M, Kaufman F R. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1

1995 NHS Economic Evaluation Database.

2366. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring

Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (...) . Health technology Diabetic treatment and teaching programme (DTTP). Type of intervention Secondary prevention Economic study type Cost-effectiveness analysis. Study population Type 1 diabetes patients, aged 15-45. The study excluded patients with significant loss of vision, renal insufficiency and severe concomitant disorders unrelated to diabetes. Setting Training took place in the hospital setting. The economic study was carried out in Moscow. Dates to which data relate Effectiveness and resource

1994 NHS Economic Evaluation Database.

2367. Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. (PubMed)

Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. To evaluate the effectiveness and acceptability of centrally organised prompting for coordinating community care of non-insulin dependent diabetic patients.Randomised single centre trial. Patients allocated to prompted care in the community or to continued attendance at hospital diabetic clinic (controls). Median follow up two years.Two hospital outpatient clinics (...) , 38 general practices, and 11 optometrists in the catchment area of a district general hospital in Islington.181 patients attending hospital outpatient clinics.There is no difference in process of medical care measures and medical outcome between prompted community care and hospital clinic care.14 hospital patients failed to receive a single review in the clinic as compared with three patients in the prompted group (chi 2 = 6.1, df = 1; p = 0.013). Follow up for retinal screening was better

Full Text available with Trip Pro

1993 BMJ

2368. Insulin prophylaxis in individuals at high risk of type I diabetes. (PubMed)

Insulin prophylaxis in individuals at high risk of type I diabetes. Prevention of type I diabetes is now a practical goal thanks to the ability to define confidently a high-risk group and the success of preventive strategies in animal models. We describe here a pilot trial of low-dose insulin to prevent diabetes in relatives of patients with type I diabetes.

1993 Lancet

2369. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. (PubMed)

Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Tight blood glucose control has been speculated to reduce late complications in insulin-dependent diabetics but results from individual studies have been inconsistent. We have done a meta-analysis of sixteen randomised trials of intensive therapy to estimate its impact on the progression of diabetic retinopathy and nephropathy and the risks of severe side-effects. In the intensive therapy group (...) treated patients. The incidence of diabetic ketoacidosis increased by 12.6 episodes per 100 person-years (95% Cl, 8.7-16.5) in the patients on continuous subcutaneous insulin infusion. Long-term intensive blood glucose control significantly reduces the risk of diabetic retinopathy and nephropathy progression but long-term continuous subcutaneous insulin infusion was associated with an increased incidence of diabetic ketoacidosis, and intensive therapy may cause more severe hypoglycaemic reactions.

1993 Lancet

2370. Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. (PubMed)

Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. Treatment of type I diabetes mellitus is hindered by the often large fluctuations in blood glucose concentration experienced by affected individuals. To determine to what extent day-to-day variation in blood glucose levels can be reduced if insulin is injected in the same anatomic region rather than in different regions using a rotational scheme, as is commonly (...) recommended, 12 type I diabetic subjects were studied. Insulin injections were given in the abdomen for 3 days and rotated among arms, abdomen, and thighs for 3 days using a crossover design with random assignment of treatment order. Blood samples for measurement of plasma glucose levels were obtained at nine scheduled times on each day. Insulin dose, diet, and physical activity were held constant for each subject. During the abdominal injection period, the mean SD of plasma glucose levels and the mean

1990 JAMA

2371. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. (PubMed)

Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. To determine the effect of moderate dietary sodium restriction on the hypertension of non-insulin-dependent (type II) diabetes.Randomised parallel controlled study of moderate sodium restriction for three months compared with usual diabetic diet, followed by randomised double blind crossover trial of sustained (...) release preparation of sodium for one month versus placebo for one month in patients continuing with sodium restriction.Patients attending diabetic outpatient clinic of city hospital.Thirty four patients with established type II diabetes complicated by mild hypertension (systolic blood pressure greater than 160 mm Hg or diastolic pressure greater than 95 mm Hg on three consecutive occasions). Patients already taking antihypertensive agents (but not diuretics) not barred from study provided

Full Text available with Trip Pro

1989 BMJ

2372. One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Point Study Group. (PubMed)

One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Point Study Group. Twenty remote-controlled insulin pumps (Siemens AG) were implanted into insulin-dependent type I diabetic patients for a one-year feasibility trial in four centres. The total observation time was 18.2 patient-years. Three pumps had to be prematurely removed after 101, 141, and 236 days. Patients self-monitored blood glucose levels with a mean of 5.5 (range 1-17) measurements

1988 Lancet

2373. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. (PubMed)

Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. This study examined the potential beneficial effects of the addition of a second-generation sulfonylurea to insulin therapy for poorly controlled type II diabetes. A randomized, double-blind, crossover experimental design was utilized in 16 type II diabetic patients for a period of eight months. Treatment with glyburide, 20 mg/d (plus insulin), compared with placebo (...) (plus insulin) resulted in a significant reduction in mean basal glucose (232 +/- 12 vs 262 +/- 11 mg/dL [12.8 vs 14.4 mmol/L]) and hemoglobin A1C (10.2% +/- 0.5% vs 10.9% +/- 03%) concentrations. Concomitant with this change, basal C-peptide and free insulin values increased with glyburide therapy, but this pharmacological agent did not alter the ability of the patient's erythrocytes to bind insulin. We conclude that in type II diabetic subjects receiving more than 28 units of insulin per day

1987 JAMA

2374. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. (PubMed)

Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. To learn more about the metabolic effects of dietary fructose and sucrose, 12 type I and 12 type II diabetic subjects were fed three isocaloric (or isoenergic) diets for eight days each according to a randomized, crossover design. The three diets provided, respectively, 21% of the energy as fructose, 23% of the energy as sucrose, and almost all carbohydrate energy as starch. The fructose diet resulted (...) in significantly lower one- and two-hour postprandial plasma glucose levels, overall mean plasma glucose levels, and urinary glucose excretion in both type I and type II subjects than did the starch diet. There were no significant differences between the sucrose and starch diets in any of the measures of glycemic control in either subject group. The fructose and sucrose diets did not significantly increase serum triglyceride values when compared with the starch diet, but both increased postprandial serum

1986 JAMA

2375. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. (PubMed)

Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. 14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period. Hydrochlorothiazide significantly increased fasting glucose by 31% (p less than 0.05) and glycosylated (...) and propranolol thus seems to cause serious disturbances in glycaemic control in type II diabetics by mechanisms independent of insulin secretion.

1985 Lancet

2376. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. (PubMed)

Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. 30 insulin-dependent diabetic patients with background retinopathy were randomised to conventional treatment (UCT) or treatment with continuous subcutaneous insulin infusion (CSII). They were followed prospectively for 1 year with fortnightly seven-sample home blood glucose measurements and retinal examinations every 6 months. Mean blood glucose and stable haemoglobin A1c during months 3-12 were

1983 Lancet